Company
Sudo
Innovative therapies for challenging conditions
Also known as Subo Biosciences
- Business model
- B2B
- Legal name
- Sudo Biosciences, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Sudo is a US-based, clinical-stage neuro-immunology company with R&D leadership based in the UK. The company is advancing a pipeline of TYK2 inhibitors for debilitating and highly prevalent diseases such as multiple sclerosis and psoriasis. Monograph participated in the Series B financing round in December 2023, co-led by Enavate Sciences and TPG Life Sciences Innovation, with participation from Frazier, Sanofi Ventures, Surveyor, and Eventid
Funding snapshot
- Total raised
- $85.8MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $63.6M2023-12-15
Funding rounds
- Round, 2023
- $63.6M2023-12-15, SEC form D sold, 15 investors
- Round, 2021
- $22.2M2021-04-20, SEC form D sold, 6 investors
Products
- Web
- SUDO-550
Loading relationship preview